PMC:7029450 / 279-1246 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"11","span":{"begin":219,"end":241},"obj":"Species"},{"id":"12","span":{"begin":243,"end":252},"obj":"Species"},{"id":"13","span":{"begin":581,"end":590},"obj":"Species"},{"id":"14","span":{"begin":663,"end":708},"obj":"Species"},{"id":"15","span":{"begin":710,"end":718},"obj":"Species"},{"id":"16","span":{"begin":725,"end":777},"obj":"Species"},{"id":"17","span":{"begin":779,"end":787},"obj":"Species"},{"id":"18","span":{"begin":814,"end":831},"obj":"Species"},{"id":"19","span":{"begin":460,"end":469},"obj":"Disease"}],"attributes":[{"id":"A11","pred":"tao:has_database_id","subj":"11","obj":"Tax:2697049"},{"id":"A12","pred":"tao:has_database_id","subj":"12","obj":"Tax:2697049"},{"id":"A13","pred":"tao:has_database_id","subj":"13","obj":"Tax:2697049"},{"id":"A14","pred":"tao:has_database_id","subj":"14","obj":"Tax:694009"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"Tax:694009"},{"id":"A16","pred":"tao:has_database_id","subj":"16","obj":"Tax:1335626"},{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"Tax:1335626"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"Tax:11308"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV\nThis document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic. The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses. ECDC will update this guidance as and when new relevant information becomes available or as required by the epidemiological situation."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T23","span":{"begin":158,"end":172},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T22","span":{"begin":230,"end":241},"obj":"NCBITaxon:11118"},{"id":"T21","span":{"begin":243,"end":252},"obj":"SP_7"},{"id":"T20","span":{"begin":581,"end":590},"obj":"SP_7"},{"id":"T19","span":{"begin":623,"end":628},"obj":"NCBITaxon:10239"},{"id":"T18","span":{"begin":629,"end":640},"obj":"UBERON:0001004"},{"id":"T17","span":{"begin":663,"end":708},"obj":"SP_10"},{"id":"T16","span":{"begin":710,"end":718},"obj":"SP_10"},{"id":"T15","span":{"begin":766,"end":777},"obj":"NCBITaxon:11118"},{"id":"T14","span":{"begin":779,"end":787},"obj":"SP_9"},{"id":"T13","span":{"begin":814,"end":823},"obj":"NCBITaxon:7719"},{"id":"T12","span":{"begin":824,"end":831},"obj":"NCBITaxon:10239"}],"text":"Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV\nThis document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic. The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses. ECDC will update this guidance as and when new relevant information becomes available or as required by the epidemiological situation."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":460,"end":469},"obj":"Disease"},{"id":"T3","span":{"begin":663,"end":696},"obj":"Disease"},{"id":"T4","span":{"begin":710,"end":718},"obj":"Disease"},{"id":"T5","span":{"begin":814,"end":823},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"}],"text":"Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV\nThis document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic. The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses. ECDC will update this guidance as and when new relevant information becomes available or as required by the epidemiological situation."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":824,"end":831},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV\nThis document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic. The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses. ECDC will update this guidance as and when new relevant information becomes available or as required by the epidemiological situation."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":30,"end":44},"obj":"Chemical"},{"id":"T2","span":{"begin":139,"end":150},"obj":"Chemical"},{"id":"T3","span":{"begin":158,"end":172},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_52217"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_33232"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_52217"}],"text":"Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV\nThis document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic. The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses. ECDC will update this guidance as and when new relevant information becomes available or as required by the epidemiological situation."}

{"project":"LitCovid-sentences","denotations":[{"id":"T4","span":{"begin":0,"end":99},"obj":"Sentence"},{"id":"T5","span":{"begin":100,"end":272},"obj":"Sentence"},{"id":"T6","span":{"begin":273,"end":470},"obj":"Sentence"},{"id":"T7","span":{"begin":471,"end":526},"obj":"Sentence"},{"id":"T8","span":{"begin":527,"end":832},"obj":"Sentence"},{"id":"T9","span":{"begin":833,"end":967},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV\nThis document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic. The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses. ECDC will update this guidance as and when new relevant information becomes available or as required by the epidemiological situation."}